Dr Reddy's Laboratories reported a sharp 69% decline in net profit for the first quarter ended June 30, 2026, posting ₹434 crore against ₹1,417 crore in the prior-year period.
The steep drop was driven by significant headwinds from the transition of its lenalidomide franchise and competitive pressures in the semaglutide active pharmaceutical ingredients (API) segment, which offset growth in the company's base business.
The results validate the considerable earnings pressure anticipated by analysts ahead of the release.
While the headline figure reflects a severe contraction, management highlighted that the underlying core business continued to expand, suggesting the decline is largely attributable to specific product-cycle transitions rather than broad-based demand weakness.
The lenalidomide transition, a known risk factor for the quarter, weighed heavily on margins, while the semaglutide API segment faced intense pricing competition.
This performance follows earlier market speculation about the impact of these specific product lines on fiscal 2027 results.